Revolution Medicines Completes Public Offering

Details

completed a public offering of 16,576,088 shares of its common stock and pre-funded warrants. The offering raised approximately $823.0 million in net proceeds for the Company. The public price per share was $46.00, and the underwriters had an option to purchase up to an additional 2,445,652 shares. A prospectus supplement and related prospectus were filed with the SEC as part of the offering.

Items reported

Exhibits (3)

About Revolution Medicines Inc.

Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.